Is this much-anticipated clinic tool setting new expectations for patient monitoring and practice management?
Sydney, Australia – 29 September 2021 INTERACT Technology Group this month has officially launched their new botulinum toxin software, BnTx INTERACT to Australian clinics described as “a new standard of care for injecting” as per Western Australian based neurologist, Dr Julian Rodrigues.
The BnTx INTERACT software is the long-held dream of Prof Con Yiannikas (Neurologist, Sydney) to consolidate the various components of treatment information into one simple system. As a specialist in treating Movement Disorders, Chronic Migraine and Spasticity with botulinum toxin, Prof Yiannikas has increasingly found that the important elements of daily practice management and patient treatment are often disparate and require recording and tracking in a congruous, efficient, and professional method and manner.
"For many years and thousands of cases, I have been conscious of the fact that the employment of only generalised patient records (in various formats), manual recording and reporting, and the capacity to access quality resources have been wanted in this field, and incredibly time-consuming, in and out of the clinic,” says Prof Yiannikas.
This is why BnTx INTERACT was developed – “to consolidate the requirement of maintaining optimal practice.” These include such features as a layered, graphical, live record of precise injection location, dose and dilution, integrated and simple patient signs and symptoms tracking, supportive anatomical visuals and footage, cases and presentations, and key efficiency advantages such as automated report generation.
Additionally, in a relatively mature area of medicine that simply does not attract trial focus, the capacity to capture data prospectively from various clinics has enormous potential to advance treatment and patient outcomes. The real-world patient data captured by BnTx INTERACT has “tremendous potential for research,” says Sydney-based neurologist, Prof Steve Vucic, referring to the centralised electronic data. He continues:
“There are countless clinical questions we [injecting neurologists] have brewing that haven’t been answered definitively… (BnTx) is probably the only way to address such questions in a very large cohort; short of doing a very expensive prospective study.”
Prof Yiannikas has described the potential to “link with a network in accumulating data and case understanding,” as “very exciting.”
BnTx INTERACT has been in development and trialled in multiple neurology clinics in Australia since 2016. Already, it has recorded over 40,000 patient sessions and some 500,000 injections – making it the largest botulinum toxin database in the country. It is now available to botulinum toxin clinics in Australia and is soon to be launched globally. An integrated patient app is coming soon in 2022.
About BnTx INTERACT
Developed by healthcare technology company, INTERACT Technology Group, BnTx INTERACT is cloud-based healthcare software and online tool for clinics specialising in the injection of botulinum toxin across various conditions such as cervical dystonia, chronic migraine and spasticity. Designed by leading Neurologist, Professor Con Yiannikas and refined with input from other leading injectors, the software contains comprehensive clinical resources such as interactive 3D anatomy with movable muscle layers, surface anatomy, cadaver and EMG footage as well as case studies. In addition, simple inputs automatically generate a report for referrers, and a data suite allows you to track key aspects of treatment over time.
For more information: www.bntxinteract.com
Media Contacts:
Holly Whittaker
Communications Manager
INTERACT Technology Group
Anthony Avvenevole
CEO
BnTx INTERACT
Comments